HTA Quarterly | Summer 2018

By Xcenda |

We take a look at whether value frameworks are the path to implementing value-based pricing, the EMA's move out of the United Kingdom, and look at the health policy trends in Canada from InnomarLive.

Heard on the Street

For the reasons described previously, it is critical that information provided by firms about their unapproved products and about unapproved uses of approved/cleared products be truthful and non-misleading.

– DRUG AND DEVICE MANUFACTURER COMMUNICATION WITH PAYORS, FORMULARY COMMITTEES, AND SIMILAR ENTITIES        – FDA GUIDANCE FOR INDUSTRY AND REVIEW STAFF.
Comments regarding requests from payors to receive information from firms about medical products that are not yet approved/cleared by FDA for any use, and about unapproved uses of approved/cleared medical products, so they can plan for and make coverage and reimbursement decisions far in advance of the effective date of such decisions.

HTA by the Numbers